Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;31(4):e13631.
doi: 10.1111/jsr.13631. Epub 2022 May 27.

Narcolepsy

Lucie Barateau  1   2   3 , Fabio Pizza  4   5 , Giuseppe Plazzi  5   6 , Yves Dauvilliers  1   2   3
Affiliations
Review

Narcolepsy

Lucie Barateau et al. J Sleep Res. 2022 Aug.

Abstract

This article addresses the clinical presentation, diagnosis, pathophysiology and management of narcolepsy type 1 and 2, with a focus on recent findings. A low level of hypocretin-1/orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease: sleepiness, cataplexy, sleep-related hallucinations and paralysis, and disrupted nocturnal sleep. The process responsible for the destruction of hypocretin neurons is highly suspected to be autoimmune, or dysimmune. Over the last two decades, remarkable progress has been made for the understanding of these mechanisms that were made possible with the development of new techniques. Conversely, narcolepsy type 2 is a less well-defined disorder, with a variable phenotype and evolution, and few reliable biomarkers discovered so far. There is a dearth of knowledge about this disorder, and its aetiology remains unclear and needs to be further explored. Treatment of narcolepsy is still nowadays only symptomatic, targeting sleepiness, cataplexy and disrupted nocturnal sleep. However, new psychostimulants have been recently developed, and the upcoming arrival of non-peptide hypocretin receptor-2 agonists should be a revolution in the management of this rare sleep disease, and maybe also for disorders beyond narcolepsy.

Keywords: narcolepsy type 1; narcolepsy type 2; orexin/hypocretin; pathophysiology; treatment.

PubMed Disclaimer

References

REFERENCES

    1. AASM (2005). ICSD-2: International classification of sleep disorders, 2nd ed. American Academy of Sleep Medicine.
    1. AASM. (2014). American Academy of sleep medicine ICSD-3: International classification of sleep disorders, 3rd ed. American Academy of Sleep Medicine.
    1. Andlauer, O., Moore, H., Hong, S.-C., Dauvilliers, Y., Kanbayashi, T., Nishino, S., Han, F., Silber, M. H., Rico, T., Einen, M., Kornum, B. R., Jennum, P., Knudsen, S., Nevsimalova, S., Poli, F., Plazzi, G., & Mignot, E. (2012). Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep, 35, 1247-1255F.
    1. Andlauer, O., Moore, H., Jouhier, L., Drake, C., Peppard, P. E., Han, F., Hong, S. C., Poli, F., Plazzi, G., O'Hara, R., Haffen, E., Roth, T., Young, T., & Mignot, E. (2013). Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurology, 70, 891-902.
    1. Antelmi, E., Pizza, F., Vandi, S., Neccia, G., Ferri, R., Bruni, O., Filardi, M., Cantalupo, G., Liguori, R., & Plazzi, G. (2017). The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. Brain: A Journal of Neurology, 140, 1669-1679.

LinkOut - more resources